Literature DB >> 17908413

Understanding the role of LH: myths and facts.

Robert Fischer1.   

Abstract

This review summarizes a series of lectures given at a recent Continuing Medical Education meeting in Hamburg, Germany (May 2007), aiming to understand the role of luteinizing hormone (LH) in follicular development during the natural menstrual cycle and controlled ovarian stimulation. Clinical situations and target groups of patients who might benefit from LH supplementation during their ovarian stimulation were discussed and defined. The lectures updated knowledge on the physiology of LH during the normal menstrual cycle and the role of LH in ovarian stimulation. The concept of the 'LH window' was presented, and the use of LH supplementation in different groups of patients undergoing controlled ovarian stimulation was discussed, including those with advanced age, hypogonadotrophic hypogonadism, pituitary down-regulation and poor response. In addition, the different ways of using LH or human chorionic gonadotrophin supplementation in ovulation induction protocols were described.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17908413     DOI: 10.1016/s1472-6483(10)60375-6

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  8 in total

1.  The effect of rLH supplementation to the GnRH-antagonist protocol on endocrine dynamics in the advanced reproductive age.

Authors:  J S Younis; I Izhaki; M Ben-Ami
Journal:  J Endocrinol Invest       Date:  2017-03-13       Impact factor: 4.256

2.  Clinical outcomes following long GnRHa ovarian stimulation with highly purified human menopausal gonadotropin plus rFSH or rFSH in patients undergoing in vitro fertilization-embryo transfer: a multi-center randomized controlled trial.

Authors:  Li Shu; Qianhua Xu; Qingxia Meng; Xue Dai; Yun Zhang; Wei Zhou; Honggang Yi; Jinyong Liu; Chunxiang Wu; Zhen Hou; Yugui Cui; Tin Chiu Li; Jiayin Liu
Journal:  Ann Transl Med       Date:  2019-04

Review 3.  Urinary Versus Recombinant Gonadotropins for Ovarian Stimulation in Women Undergoing Treatment with Assisted Reproductive Technology.

Authors:  Ameet Patki; Himanshu Bavishi; Chandravati Kumari; Jayarani Kamraj; M Venugopal; K U Kunjimoideen; Poornima Nadkarni; Samundi Sankari; Sunil Chaudhary; M J Sangeeta; C S Manjunath; Pratap Kumar
Journal:  J Hum Reprod Sci       Date:  2018 Apr-Jun

4.  Luteinizing hormone changes in gonadotropin-releasing hormone antagonist protocol in in vitro fertilization cycles: A cross-sectional study.

Authors:  Batool Hosein Rashidi; Roya Kabodmehri; Mamak Shariat; Ensieh Shahrokh Tehraninejad; Alireza Abdollahi; Maryam Bagheri; Fedieh Hagholahi
Journal:  Int J Reprod Biomed       Date:  2019-05-05

5.  Assessment of the biopotency of follitropin alfa and lutropin alfa combined in one injection: a comparative trial in Sprague-Dawley rats.

Authors:  Michael Alper; Randal Meyer; Chris Dekkers; Diego Ezcurra; Joan Schertz; Eduardo Kelly
Journal:  Reprod Biol Endocrinol       Date:  2008-07-22       Impact factor: 5.211

6.  A large, multicentre, observational, post-marketing surveillance study of the 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice for assisted reproductive technology.

Authors:  Klaus Bühler; Olaf G J Naether; Wilma Bilger
Journal:  Reprod Biol Endocrinol       Date:  2014-01-14       Impact factor: 5.211

Review 7.  Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis.

Authors:  Philippe Lehert; Efstratios M Kolibianakis; Christos A Venetis; Joan Schertz; Helen Saunders; Pablo Arriagada; Samuel Copt; Basil Tarlatzis
Journal:  Reprod Biol Endocrinol       Date:  2014-02-20       Impact factor: 5.211

8.  Patients With Deep Ovarian Suppression Following GnRH Agonist Long Protocol May Benefit From a Modified GnRH Antagonist Protocol: A Retrospective Cohort Study.

Authors:  Shan Liu; Minghui Liu; Lingxiu Li; Huanhuan Li; Danni Qu; Haiying Ren; Hui Su; Yang Zhang; Yuan Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-13       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.